Brittany Lovely | Authors

Articles

Sacituzumab Govitecan Sustains Efficacy Across HER2 Expressions in TNBC

May 06, 2022

Metastatic triple-negative breast cancer appears to derive clinical benefit from sacituzumab govitecan-hziy overtime, regardless of patients’ HER2 expression, according to a post hoc analysis of the phase 3 ASCENT trial.